MX2007004596A - Nitrobenzoindoles y su uso en terapia del cancer. - Google Patents

Nitrobenzoindoles y su uso en terapia del cancer.

Info

Publication number
MX2007004596A
MX2007004596A MX2007004596A MX2007004596A MX2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A MX 2007004596 A MX2007004596 A MX 2007004596A
Authority
MX
Mexico
Prior art keywords
cancer therapy
nitrobenzindoles
drugs
radiosensitizers
indoles
Prior art date
Application number
MX2007004596A
Other languages
English (en)
Spanish (es)
Inventor
William Alexander Denny
William Robert Wilson
Shangjin Yang
Ralph James Stevenson
Moana Tercel
Graham John Atwell
Adam Vorn Patterson
Frederik Bastiaan Pruijn
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of MX2007004596A publication Critical patent/MX2007004596A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • C07F9/5728Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/60Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
MX2007004596A 2004-10-22 2005-10-21 Nitrobenzoindoles y su uso en terapia del cancer. MX2007004596A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ536107A NZ536107A (en) 2004-10-22 2004-10-22 Nitrobenzindoles and their use in cancer therapy
PCT/NZ2005/000278 WO2006043839A1 (en) 2004-10-22 2005-10-21 Nitrobenzindoles and their use in cancer therapy

Publications (1)

Publication Number Publication Date
MX2007004596A true MX2007004596A (es) 2007-06-22

Family

ID=36203204

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004596A MX2007004596A (es) 2004-10-22 2005-10-21 Nitrobenzoindoles y su uso en terapia del cancer.

Country Status (14)

Country Link
US (1) US7718688B2 (enExample)
EP (1) EP1809603A4 (enExample)
JP (1) JP2008517905A (enExample)
KR (1) KR20070083806A (enExample)
CN (1) CN101044114B (enExample)
AU (1) AU2005296389B2 (enExample)
BR (1) BRPI0517285A (enExample)
CA (1) CA2584702A1 (enExample)
IL (1) IL182652A0 (enExample)
MX (1) MX2007004596A (enExample)
NZ (1) NZ536107A (enExample)
RU (1) RU2007118938A (enExample)
WO (1) WO2006043839A1 (enExample)
ZA (1) ZA200703699B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5346589B2 (ja) * 2006-02-02 2013-11-20 シンタルガ・ビーブイ 水溶性cc−1065類似体及びその接合体
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
US8076491B2 (en) 2007-08-21 2011-12-13 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
HUE025137T2 (en) 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
NZ571028A (en) * 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
HUE035798T2 (en) 2008-11-03 2018-05-28 Syntarga Bv CC-1065 analogues and conjugates
HUE030846T2 (en) 2010-04-21 2017-06-28 Syntarga Bv Conjugates of cc-1065 analogs and bifunctional linkers
CN102827061A (zh) * 2012-09-19 2012-12-19 兰州大学 5,6,7-三甲氧基吲哚类衍生物、制备方法及用途
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2948184B1 (en) 2014-01-10 2016-03-23 Synthon Biopharmaceuticals B.V. Duocarmycin adcs showing improved in vivo antitumor activity
RU2686085C2 (ru) 2014-01-10 2019-04-24 Синтон Байофармасьютикалс Б. В. Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
LT3092010T (lt) 2014-01-10 2018-10-25 Synthon Biopharmaceuticals B.V. Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų
DK3160513T3 (da) 2014-06-30 2020-04-06 Glykos Finland Oy Saccharidderivat af en toksisk payload og antistofkonjugater deraf
JPWO2019004413A1 (ja) * 2017-06-30 2020-05-07 東レ株式会社 インドリン誘導体及びそれを含む細胞毒性剤
CN112724068A (zh) * 2020-12-30 2021-04-30 蔡桂坡 具有hdac抑制活性的吲哚类衍生物的合成方法及肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938474B1 (en) * 1996-09-12 2005-11-23 Auckland Uniservices Limited Cyclopropylindole compounds and their use as prodrugs
US7192977B2 (en) * 2001-02-22 2007-03-20 School Of Pharmacy Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
US7235578B2 (en) * 2002-05-17 2007-06-26 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
NZ529249A (en) 2003-10-31 2006-04-28 Auckland Uniservices Ltd Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic

Also Published As

Publication number Publication date
CA2584702A1 (en) 2006-04-27
BRPI0517285A (pt) 2008-10-07
RU2007118938A (ru) 2008-11-27
EP1809603A4 (en) 2009-09-02
AU2005296389B2 (en) 2012-03-15
ZA200703699B (en) 2008-10-29
US7718688B2 (en) 2010-05-18
WO2006043839A1 (en) 2006-04-27
AU2005296389A1 (en) 2006-04-27
KR20070083806A (ko) 2007-08-24
CN101044114B (zh) 2012-02-15
CN101044114A (zh) 2007-09-26
IL182652A0 (en) 2007-07-24
NZ536107A (en) 2007-06-29
US20080119442A1 (en) 2008-05-22
JP2008517905A (ja) 2008-05-29
EP1809603A1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
MX2007004596A (es) Nitrobenzoindoles y su uso en terapia del cancer.
IL186230A0 (en) Anticancer combination therapy using sunitinib malate
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2010110685A8 (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
PL1951729T3 (pl) Pochodne pirymidyny połączone przez atom tlenu
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
UA105210C2 (ru) Противораковая вакцина и ее применение
WO2008089397A3 (en) Adrb2 cancer markers
MY146112A (en) Long-term feed - cancer patient
WO2005067980A3 (en) Design of therapeutics and therapeutics
EP2004637A1 (en) Substituted ring fused azines and their use in cancer therapy
WO2011054837A3 (de) Bifunktionale prodrugs und drugs
TW200600091A (en) Sulfonylethyl phosphorodiamidates
WO2007019308A3 (en) Illudin analogs useful as anticancer agents
EP1713474A4 (en) INDIRUBINE DERIVATIVES WITH ANTICANCER PROPERTIES AGAINST CANCER CELLS IN HUMANS
PL2185561T3 (pl) Pochodne 1,2,3,4-tetrahydropirolo(1,2-a)pirazyno-6-karboksamidów i 2,3,4,5-tetrahydropirolo(1,2-a)-diazepino-7-karboksamidów, ich wytwarzanie i zastosowanie terapeutyczne
TN2009000119A1 (en) Combination drug
WO2004026846A8 (en) Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
WO2011056566A3 (en) Compounds and methods for treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
WO2007087462A3 (en) Methods and compositions for cancer therapy using a novel adenovirus
WO2005076888A3 (en) Anti-cancer therapies
PT1803456E (pt) Composições farmacêuticas que compreendem l-733060 para utilização no tratamento de tumores cancerígenos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal